SCHEMBL569675

SCHEMBL569675

CC(C)(C)ON(C(=O)O)S(=O)(=O)c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.56
HTT P42858 3/20 0.52
PTGES O14684 4/20 0.49
PGR P06401 3/20 0.48
FFAR1 O14842 1/20 0.47
MMP2 P08253 5/20 0.46
MMP13 P45452 5/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
DAGLA Q9Y4D2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
NR3C1 P04150 3/20 0.46
MMP1 P03956 3/20 0.46
MMP9 P14780 3/20 0.46
MMP8 P22894 3/20 0.46
MMP14 P50281 3/20 0.46
MMP16 P51512 2/20 0.46
MMP3 P08254 2/20 0.46
MMP12 P39900 1/20 0.46
ALOX5 P09917 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1133773 0.74 LMNA (0.59) LMNAHTTPTGESMMP2MMP13
SCHEMBL14507726 0.71 MMP13 (0.61) LMNAHTTPGRFFAR1MMP2
SCHEMBL7350929 0.70 LMNA (0.51) LMNAHTTPTGESPGRFFAR1
SCHEMBL11887252 0.70 SOS1 (0.55) LMNAHTTPGRFFAR1MMP2
SCHEMBL1133911 0.70 MMP2 (0.82) LMNAHTTPTGESMMP2MMP13
SCHEMBL12895710 0.70 SOS1 (0.58) LMNAHTTPGRFFAR1MMP2
SCHEMBL11182312 0.69 LMNA (1.00) LMNAHTTPTGESPGRFFAR1
SCHEMBL6324817 0.69 LMNA (0.60) LMNAHTTPTGESPGRFFAR1
SCHEMBL6324814 0.69 LMNA (0.60) LMNAHTTPTGESPGRFFAR1
SCHEMBL4779263 0.68 ADAMTS4 (0.50) HTTPTGESMMP2MMP13MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8993544-B2 Carbamoylphosphonates as inhibitors and uses thereof YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) 2015-03-31 US disclosed
EP-2393495-B1 CARBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF YISSUM RES DEV CO (IL) 2014-07-23 EP disclosed
US-20120035140-A1 CARBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) 2012-02-09 US disclosed
EP-2393495-A1 CARJBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. (IL) 2011-12-14 EP disclosed
WO-2010089752-A1 CARJBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) 2010-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035140-A1 CARBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF MMP9, MMP26, MMP25 LMNA 2584/4885HTT 1954/4885PTGES 1774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.